Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Illumina, Inc. (ILMN) vs Msci Inc (MSCI) Price & Performance

Illumina, Inc.Trade

Price performance (Past 24H)

Key statistics

Illumina, Inc. vs Msci Inc — how do they compare? Illumina, Inc. trades at $265.01 (market cap $39.95B), while Msci Inc trades at $561.75 (market cap $40.38B). The key difference: Illumina, Inc. and Msci Inc are close in size by market cap, and Msci Inc pays a 1.48% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Msci Inc for 82 Days on average.

ILMNMSCI
Market Cap
$39.95B$40.38B
Volume
3,169,503414,140
Sector
HealthFinancials
52-Week High
$293.69$643.83
52-Week Low
$91.00$511.84
Typical Hold Time
83 Days82 Days
Enterprise Value
$41.31B$46.54B
Dividend Yield
—1.48%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illumina, Inc.

Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.

The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.

Msci Inc

MSCI trades at $555.38, up 0.08% on the day, with a neutral technical signal. The stock shows strong fundamentals with a 40.73% net income margin and consistent revenue growth, reaching $3.13B in 2025. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed slightly. Analyst sentiment is bullish with a 74% buy rating and a $701.71 consensus price target, suggesting significant upside. The company maintains robust cash flow from operations at $1.59B in 2025.

Outlook remains positive due to high profitability and analyst confidence, but risks include elevated valuation multiples and high long-term debt of $4.51B. The upcoming Q3 2026 earnings call on October 20, 2026, will be a key catalyst. Investors should weigh the strong growth trajectory against debt levels and market volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ILMN
96% Buy4% Sell
Avg holding period · 83 Days
MSCI
0% Buy100% Sell
Avg holding period · 82 Days

Top news

Latest headlines on both assets

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN →

About Msci Inc

MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.

Read more on MSCI →